— Know what they know.
/
Not Investment Advice

COO

NASDAQ · USD
The Cooper Companies, Inc.
Healthcare · Medical - Instruments & Supplies
CEO Albert G. White Employees 15,000 R&D / revenue 4.2%
Last price
$57.94+0.94%last session
Market cap
$11.0B
P/E (TTM)
19.8x
From 52w high
−35.5%
From 52w low
+13.6%
1-year return
−19.0%
RSI 14 · vs SMA200
50.3 · −17.3%
IS score
69.2/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)

One year, rebased to 100

COO   SPY   XLV (sector ETF) · weekly closes
8090100110120Jan 26Apr 26Jul 26Oct 26XLV 124SPY 116COO 81

Score DNA

Each bar is a 0-100 score within the scored universe
61
Profitability
60
Growth
45
Value
88
Momentum
80
Risk (safety)
79
Quality
56
Balance sheet
74
Earnings quality

Flags

Strengths
✓ FCF yield 5%+✓ Insider buying✓ Congress buying
Warnings
None of the computed warning flags fires for COO (Altman, Beneish, accruals, FCF, dilution).
Observations
Moat model: Weak, Efficient ScalePiotroski 6 / 9Altman Z 3.3Beta 0.824 of 4 smart-money sources active

Smart-money strip

Each disclosure source on its own window. Filings coinciding is not coordination.
INSForm 4 · 180 days
Insider open-market buys
5
$1.88M bought
No Form 144 notices in 12 months
CONGSTOCK Act · 180 days
Congressional purchases
15
Last disclosed purchase 2026-09-17
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2026-06-30
Net change in institutional holders
+2
113 new holders, 102 closed
673 filers hold 109.2% · 256 added, 239 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+178
806 funds adding shares
628 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
16.5%
20-day avg 25.9%, 50-day avg 34.4%
Latest 9.4 pp under its 20-day average · a flow, not short interest

Key financials · FY2025

USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.
Income statement
Revenue$4.1B
Revenue growth YoY+5.1%
Gross margin60.7%
Operating income$682.9M
Operating margin16.7%
Net income$374.9M
Net margin9.2%
EPS (diluted)$1.87
Cash flow
Operating cash flow$796.1M
Capital expenditure$362.4M
Free cash flow$433.7M
FCF conversion (FCF / OCF)54.5%
Stock-based compensation$0
FCF less SBC$433.7M
Buybacks$290.1M
Dividends$0
Balance sheet & returns
Cash & short-term investments$110.6M
Total debt$2.5B
Net debt$2.4B
Shareholders' equity$8.2B
Goodwill & intangibles$5.4B
Debt / equity0.31
ROE (TTM)6.9%
ROIC (TTM)4.8%
Operating margin by fiscal year
17.3%FY202115.3%FY202214.8%FY202318.1%FY202416.7%FY2025
Revenue $2.9B (FY2021) to $4.1B (FY2025), a 8.8% CAGR.

Valuation

P/E (TTM)19.8x
EV / EBITDA14.7x
Price / sales2.60x
Price / FCF16.3x
FCF yield6.15%
Buyback yield2.63%
SBC / revenue0.0%
Price / book1.35x
Forward P/E FY202612.8x
Forward P/E FY202712.3x
Forward P/E FY202811.3x
Forward multiples divide today's price by Street EPS estimates. Street mean target $65.63 across 8 analysts last quarter is theirs, not ours.

COO vs industry median

111 companies in Medical - Instruments & Supplies
Gross margin 63.6% 53.7% Operating margin 12.9% 6.7% Net margin 13.5% 4.3% ROIC 4.8% 7.2%
COO (TTM)Industry median Asset turnover 0.33 vs industry 0.60 · financial leverage 1.52

Earnings delivery

Next report 2026-12-03 · consensus EPS $1.07
92%
beat rate, 11 of 12 quarters
+3.5%
median EPS surprise
11
longest beat streak
+0+9+3+5+4+1+3+3+4+7+10+3
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-12-07 to 2026-09-09. Bars cap at ±60%.

Peers

Market-cap band, not the industry cohort above
CompanyMkt capP/EROENet marginRev growth12m return
COO The Cooper Companies, Inc. $11.0B19.8x6.9%13.5%+5.1% −19.0%
AVTR Avantor, Inc. $11.1Bn/m-9.7%2.3%−1.6% +12.7%
RGEN Repligen Corporation $11.1B237.1x2.0%2.5%+16.5% +13.5%
BAX Baxter International Inc. $13.1Bn/m-15.7%4.3%+5.4% +10.3%
SOLV Solventum Corporation $14.6B10.4x34.0%4.2%−0.9% +20.1%
ATR AptarGroup, Inc. $7.9B22.2x13.6%8.5%+8.9% —
HOLX Hologic, Inc. $17.0B30.3x10.9%17.1%+2.2% —
BLCO Bausch + Lomb Corporation $5.9Bn/m-2.7%-1.0%+8.8% —
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.

Recent 8-K filings

2026-09-09Earnings Release; Other Events; Exhibits
2026-06-04Earnings Release; Other Events; Exhibits
2026-05-04Officer/Director Change
2026-04-08Shareholder Vote
2026-03-05Results of Operations and Financial Condition; Financial Statements and Exhibits
2026-02-04Entry into Material Definitive Agreement; Financial Statements and Exhibits

Context

Shares outstanding190,155,294
Free float99.4%
Institutional ownership109.2%
Beta0.82
Dividend yield0.00%
Last dividend$0.01 on 2023-07-26
50 / 200-day average$63.86 / $70.16
Large-cap Healthcare median P/E29.7x

Full factsheet

The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Weak).

Read it in the browser Download (PDF)

All fundamentals · 140 measures in 13 categories

Percentile = where COO sits among 26 scored companies in Medical - Instruments & Supplies (0 = lowest value, 100 = highest). It is a position, not a grade.
ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)

Valuation

MeasureCOOIndustry medianIndustry percentileSector median
P/E (TTM) 19.3x 43.3x
13th		 27.6x
PEG (P/E ÷ 3-yr EPS CAGR) 0.67 1.31
29th		 1.28
Price / sales 2.6x 2.4x
58th		 3.7x
Price / book 1.3x 2.9x
17th		 3.6x
Price / tangible book 4.7x 7.6x
13th		 5.8x
Price / free cash flow 16.3x 25.3x
24th		 21.2x
Price / operating cash flow 10.7x 18.6x
18th		 17.1x
Enterprise value $13.4B $6.9B
68th		 $2.5B
EV / sales 3.2x 2.7x
62nd		 3.8x
EV / EBITDA 14.7x 20.4x
25th		 16.2x
EV / EBIT 25.5x 32.2x
41st		 23.0x
EV / free cash flow 19.8x 29.9x
14th		 24.6x
Earnings yield 5.2% 0.6%
92nd		 -0.3%
FCF yield 6.2% 3.8%
80th		 1.7%
Operating cash flow yield 9.4% 4.9%
84th		 2.9%
Graham number (per share) $53.45 $48.19
57th		 $26.70

Profitability (TTM)

MeasureCOOIndustry medianIndustry percentileSector median
Gross margin 63.6% 53.8%
80th		 65.1%
EBITDA margin 21.5% 13.9%
67th		 6.6%
Operating margin 12.9% 9.8%
75th		 3.5%
EBIT margin 12.4% 6.8%
67th		 2.4%
Net margin 13.5% 1.9%
79th		 0.3%
NOPAT margin 15.9% 6.6%
75th		 2.7%
FCF margin 16.0% 7.9%
83rd		 4.3%
Operating cash flow margin 24.4% 11.4%
88th		 7.1%
R&D / revenue 4.0% 5.9%
21st		 12.4%
SG&A / revenue 44.5% 36.9%
79th		 37.9%
Stock comp / revenue 0.0% 1.7%
0th		 4.5%
Effective tax rate -23.3% 21.0%
0th		 21.0%

Returns on capital

MeasureCOOIndustry medianIndustry percentileSector median
ROE (on average equity) 6.8% 2.0%
71st		 0.8%
ROA 4.6% 1.2%
68th		 -0.3%
ROIC 6.3% 3.8%
60th		 5.5%
ROCE 4.9% 3.9%
52nd		 2.3%
Return on tangible assets 4.2% 3.3%
56th		 1.7%
Cash ROIC (OCF / invested capital) 9.6% 8.3%
64th		 9.7%
Gross profitability (GP / assets) 21.3% 24.9%
40th		 29.9%
ROIC, 3-yr average 5.2% 2.1%
67th		 2.6%
ROIC, 5-yr average 4.3% -0.2%
67th		 3.2%
ROE, 5-yr average 5.2% -0.8%
62nd		 -4.9%
Incremental ROIC 408.5% 34.6%
96th		 17.2%

Growth

MeasureCOOIndustry medianIndustry percentileSector median
Revenue growth (TTM YoY) 4.7% 8.8%
35th		 10.5%
Revenue growth (QoQ) -1.4% 4.8%
4th		 7.2%
Revenue CAGR, 3 yr 6.4% 3.5%
67th		 10.7%
Revenue CAGR, 5 yr 8.3% 7.0%
53rd		 12.1%
Gross profit CAGR, 3 yr 5.6% 2.8%
67th		 10.6%
Operating income CAGR, 3 yr 2.8% 9.5%
36th		 11.7%
Net income growth (TTM YoY) 39.8% 20.4%
80th		 17.5%
Net income CAGR, 3 yr 27.5% 15.3%
82nd		 11.3%
EPS growth (TTM YoY) 45.1% 22.3%
80th		 19.2%
EPS CAGR, 3 yr 28.8% 15.5%
82nd		 14.0%
EPS CAGR, 5 yr -45.0% -4.8%
0th		 8.1%
FCF growth (TTM YoY) 64.6% 14.5%
76th		 18.6%
FCF CAGR, 3 yr 45.2% 24.8%
79th		 15.4%
Operating cash flow CAGR, 3 yr 22.4% 8.4%
62nd		 11.9%
Book value CAGR, 3 yr 4.5% 1.8%
71st		 2.1%
Dividend CAGR, 3 yr —
Sustainable growth rate 6.8% 6.8%
50th		 12.2%

Margin history & stability

MeasureCOOIndustry medianIndustry percentileSector median
Gross margin, 3-yr average 65.7% 54.6%
77th		 62.6%
Operating margin, 3-yr average 16.0% 7.2%
77th		 1.0%
Net margin, 3-yr average 11.0% 2.3%
82nd		 -2.6%
FCF margin, 3-yr average 10.4% 8.8%
64th		 3.2%
Revenue stability (0-1) 0.99 0.73
83rd		 0.80
Earnings stability (0-1) 0.37 0.40
48th		 0.37
Margin stability (0-1) 0.98 0.96
77th		 0.93

Liquidity (latest quarter)

MeasureCOOIndustry medianIndustry percentileSector median
Cash & short-term investments $154.7M $316.3M
12th		 $330.9M
Net cash (− = net debt) −$2.4B −$416.9M
28th		 $8.4M
Working capital $414.9M $705.4M
40th		 $381.1M
Current ratio 1.22 2.54
8th		 3.02
Quick ratio 0.73 2.12
4th		 2.51
Cash ratio (cash + ST investments / current liabilities) 0.08 0.83
4th		 1.43
Defensive interval (days) 160 days 399 days
12th		 415 days

Leverage & solvency (latest quarter)

MeasureCOOIndustry medianIndustry percentileSector median
Total debt $2.5B $1.0B
72nd		 $289.1M
Debt / equity 0.31 0.49
33rd		 0.45
Net debt / equity 0.29 0.22
54th		 −0.13
Debt / assets 20.1% 28.5%
32nd		 24.4%
Debt / capital 23.4% 32.8%
33rd		 31.1%
Debt / EBITDA 2.79 3.77
45th		 2.62
Net debt / EBITDA 2.62 1.79
55th		 1.42
Interest coverage (EBIT / interest) 5.6x 2.3x
67th		 2.1x
Cash interest coverage 10.9x 5.3x
81st		 3.6x
Debt payback (years of OCF) 2.5 yrs 5.1 yrs
32nd		 2.7 yrs
Liabilities / assets 34.3% 43.2%
36th		 49.8%
IS credit model rating A- — —
Implied credit spread (bps) 175 288
40th		 225

Efficiency

MeasureCOOIndustry medianIndustry percentileSector median
Asset turnover 0.34 0.55
12th		 0.56
Fixed asset turnover 1.98 3.55
12th		 4.87
Inventory turnover 1.7 2.7
12th		 2.7
Receivables turnover 5.4 6.3
24th		 6.4
Days sales outstanding 68 days 58 days
76th		 57 days
Days inventory outstanding 212 days 138 days
88th		 136 days
Days payables outstanding 60 days 55 days
64th		 59 days
Cash conversion cycle (days) 220 days 124 days
92nd		 70 days
Capex / revenue 8.4% 3.9%
92nd		 2.6%
Capex / depreciation 0.93 0.48
88th		 0.55
Operating expense ratio 41.5% 43.1%
46th		 56.5%

Cash flow & earnings quality

MeasureCOOIndustry medianIndustry percentileSector median
Operating cash flow / net income 1.81 1.97
40th		 1.61
FCF / net income 1.19 1.64
40th		 1.36
FCF / operating cash flow 65.6% 74.0%
38th		 81.2%
Capex / operating cash flow 34.4% 26.0%
62nd		 18.8%
Accruals ratio -3.7% -5.1%
68th		 -5.4%
Sloan accruals ratio -8.8% -2.4%
8th		 -1.3%
Earnings quality score (0-1) 1.00 1.00
47th		 0.75

Dividends & buybacks

MeasureCOOIndustry medianIndustry percentileSector median
Dividend yield 0.0% 0.0%
0th		 0.0%
Dividend per share (TTM) $0.00 $0.00
0th		 $0.00
Payout ratio (dividends / net income) 0.0% 0.0%
0th		 0.0%
Dividends / FCF 0.0% 0.0%
0th		 0.0%
Dividend growth (YoY) —
Buyback yield 0.5% 0.5%
52nd		 0.0%
Shareholder yield (dividends + buybacks) 0.5% 0.7%
44th		 0.0%
Share count change (YoY) -3.6% 0.0%
12th		 2.0%
Buybacks, last 5 years $1.2B $56.9M
80th		 $0

Scores & forensic checks

MeasureCOOIndustry medianIndustry percentileSector median
IS score 69 43
84th		 46
IS profitability 61 32
84th		 22
IS growth 60 57
57th		 60
IS value 45 42
64th		 39
IS momentum 88 70
74th		 67
IS risk (safety) 80 80
48th		 80
IS quality 79 58
80th		 49
IS balance sheet 56 53
52nd		 55
IS earnings quality 74 60
72nd		 56
IS cash flow 70 51
80th		 41
Piotroski F-score (0-9) 6 6
48th		 5
Altman Z-score 3.3 3.2
56th		 3.2
Beneish M-score −2.62 −2.68
74th		 −2.62
Ohlson O-score −9.33 −8.33
28th		 −7.16
IS credit score 66 58
56th		 62

Per share

MeasureCOOIndustry medianIndustry percentileSector median
EPS, diluted (TTM) $2.95 $0.50
76th		 −$0.03
Book value per share $43.06 $18.30
80th		 $7.10
Tangible book per share $15.54 $3.11
80th		 $1.91
Revenue per share $21.91 $17.79
56th		 $9.38
FCF per share $3.51 $1.57
72nd		 $0.46
Operating cash flow per share $5.34 $2.10
72nd		 $0.93
Cash per share $0.80 $3.47
4th		 $3.51

Size (TTM)

MeasureCOOIndustry medianIndustry percentileSector median
Market cap $11.0B $5.4B
64th		 $2.4B
Revenue $4.2B $2.7B
68th		 $770.2M
EBITDA $910.3M $262.0M
80th		 $56.1M
Net income $570.3M $35.8M
84th		 −$3.3M
Free cash flow $678.0M $158.7M
80th		 $41.2M
Total assets $12.7B $4.6B
76th		 $1.3B
Shareholders' equity $8.3B $2.4B
88th		 $568.4M
Employees 15,000 11,685
76th		 1,086

Insider transactions, last 6 months

Form 4 · most recent 12
DateInsiderTypeSharesPriceValueOwned after
2026-09-16Kurzius Lawrence Erik
Director
 Open-market buy 10,000$54.93$549,32031,099
2026-09-14Rosebrough Walter M Jr
Director
 Open-market buy 3,000$54.29$162,87020,000
2026-09-14Kurzius Lawrence Erik
Director
 Open-market buy 10,000$53.91$539,15021,099
2026-09-11Rosebrough Walter M Jr
Director
 Open-market buy 7,000$54.11$378,77017,000
2026-09-11Keel Paul A
Director
 Open-market buy 4,701$53.18$250,0004,701
2026-07-01Keel Paul A
Director
 Award / grant 2,814——2,814

Shares acquired vs disposed, by month

acquired disposed · all Form 4 types
AprJulSep

By transaction type, 6 months

TypeDirectionFilingsSharesValue
Award / grantAcquired12,814—
Open-market buyAcquired534,701$1.9M
—Disposed10—
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.

Form 144 notices

FiledFilerShares proposedEst. proceeds
2024-09-19Albert G. White Iii114,992$12.7M
2024-09-10Agostino Ricupati1,601$172,950
2024-09-05Brian G. Andrews24,788$2.6M
2024-09-04Daniel Mcbride114,992$12.1M
A Form 144 is notice of a proposed sale, not a confirmed one.

Congress trades

12 months: House 19 trades (19 purchases) · Senate 1 (1 purchases)
TradedMemberChamberTypeAmountDisclosed
2026-09-17Ro KhannaHousePurchase$1,001 - $15,0002026-10-09
2026-09-17Ro KhannaHousePurchase$1,001 - $15,0002026-10-09
2026-09-16Ro KhannaHousePurchase$1,001 - $15,0002026-10-09
2026-09-14Ro KhannaHousePurchase$1,001 - $15,0002026-10-09
2026-03-27Alan ArmstrongSenatePurchase$1,001 - $15,0002026-07-21
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.

Largest 13F holders

Quarter to 2026-06-30, the latest most managers have filed
ManagerSharesValue% of shares out
BlackRock, Inc.15,029,453$1.1B7.90%
VANGUARD CAPITAL MANAGEMENT LLC12,758,769$914.9M6.71%
STATE STREET CORP8,892,643$637.7M4.68%
VANGUARD PORTFOLIO MANAGEMENT LLC8,669,690$621.7M4.56%
T. Rowe Price Investment Management, Inc.7,429,535$532.8M3.91%
BROWNING WEST LP7,195,428$516.0M3.78%
PRICE T ROWE ASSOCIATES INC /MD/5,579,650$400.1M2.93%
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC5,430,282$389.4M2.86%
GEODE CAPITAL MANAGEMENT, LLC5,359,812$382.9M2.82%
FRANKLIN RESOURCES INC5,096,888$365.5M2.68%
GENERATION INVESTMENT MANAGEMENT LLP4,968,673$356.3M2.61%
Jupiter Topco LLC4,254,267$305.1M2.24%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP4,004,357$287.2M2.11%
Longview Partners3,940,007$282.5M2.07%
CITADEL ADVISORS LLC3,872,397$277.7M2.04%

Institutional ownership by quarter

2023-092026-06109.2%
% of shares held by 13F filers
2023-092026-06673
Number of 13F filers holding

Holder changes by quarter

QuarterHoldersOwnershipNewIncreasedReducedClosed
2026-06-30673109.2%113256239102
2026-03-31671105.6%10524323685
2025-12-31665104.7%12321725068
2025-09-30626105.5%8821226075
2025-06-30623103.9%8323824090
2025-03-31637102.6%71230249102
2024-12-31674101.1%10023824969
2024-09-3065198.8%8723125147
2024-06-3061999.5%9926018646
2024-03-3157596.8%569510
2023-12-3160.8%5000
2023-09-3010.0%0000

Schedule 13D / 13G filers

FiledFormFiler% of classShares
2026-05-14SCHEDULE 13G/ACapital World Investors4.0%7,834,830
2026-04-29SCHEDULE 13GVanguard Capital Management7.5%14,664,697
2026-03-26SCHEDULE 13G/AThe Vanguard Group0.0%0
2025-11-13SCHEDULE 13GCapital World Investors5.5%10,973,924
Required above 5% of a class; 13G is the passive form.

ETFs with the largest holding

ETFWeight in fundHolding value
VITSX0.02%$350.9M
VTSAX0.02%$350.9M
VSMPX0.02%$350.9M
VTI0.02%$350.9M
VFFSX0.02%$289.6M
VFINX0.02%$289.6M

Share structure

Shares outstanding190,155,294
Float188,943,713
Free float99.4%

Income statement

Fiscal years, USD
FY2021FY2022FY2023FY2024FY2025
Revenue$2.9B$3.3B$3.6B$3.9B$4.1B
Cost of revenue$966.7M$1.2B$1.2B$1.3B$1.6B
Gross profit$2.0B$2.1B$2.4B$2.6B$2.5B
R&D$92.7M$110.3M$137.4M$155.1M$172.2M
SG&A$1.2B$1.3B$1.5B$1.5B$1.6B
Operating income$505.8M$507.6M$533.1M$705.7M$682.9M
EBITDA$823.9M$878.7M$885.9M$1.1B$1.1B
Pretax income$491.5M$475.3M$412.9M$582.3M$566.5M
Income tax−$2.5B$89.5M$118.7M$190.0M$191.6M
Net income$2.9B$385.8M$294.2M$392.3M$374.9M
EPS, diluted$59.07$1.94$1.48$1.96$1.87
Diluted shares49.9M198.8M199.2M200.4M200.0M

Balance sheet

FY2021FY2022FY2023FY2024FY2025
Cash & short-term investments$95.9M$138.2M$120.8M$107.6M$110.6M
Receivables$515.3M$557.8M$609.7M$717.0M$829.0M
Inventory$585.6M$628.7M$735.6M$802.7M$846.0M
Total current assets$1.5B$1.5B$1.7B$2.0B$2.1B
PP&E, net$1.3B$1.4B$1.6B$1.9B$2.1B
Goodwill & intangibles$3.8B$5.5B$5.3B$5.6B$5.4B
Total assets$9.6B$11.5B$11.7B$12.3B$12.4B
Accounts payable$161.4M$248.8M$261.9M$260.5M$300.4M
Total current liabilities$732.1M$1.3B$969.0M$1.0B$1.1B
Long-term debt$1.4B$2.3B$2.5B$2.5B$2.5B
Total liabilities$2.7B$4.3B$4.1B$4.2B$4.2B
Shareholders' equity$6.9B$7.2B$7.6B$8.1B$8.2B

Cash flow statement

Outflows are negative
FY2021FY2022FY2023FY2024FY2025
Net income$2.9B$385.8M$294.2M$392.3M$374.9M
Depreciation & amortization$309.3M$346.1M$367.7M$413.8M$423.0M
Stock-based compensation$43.8M$54.2M$62.1M$0$0
Change in working capital−$149.9M−$174.0M−$218.8M−$333.7M−$284.8M
Operating cash flow$738.6M$692.4M$607.5M$709.3M$796.1M
Capital expenditure−$214.4M−$242.0M−$392.5M−$421.2M−$362.4M
Free cash flow$524.2M$450.4M$215.0M$288.1M$433.7M
Investing cash flow−$450.3M−$1.8B−$449.0M−$764.6M−$372.9M
Net debt issued / repaid−$309.9M$1.3B−$180.8M$5.6M−$79.9M
Buybacks−$24.8M−$78.5M−$23.0M$0−$290.1M
Dividends paid−$3.0M−$3.0M−$3.0M$0$0

Ratio history

Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end
FY2021FY2022FY2023FY2024FY2025
Gross margin66.9%64.7%65.6%66.6%64.3%
Operating margin17.3%15.3%14.8%18.1%16.7%
Net margin100.8%11.7%8.2%10.1%9.2%
FCF margin17.9%13.6%6.0%7.4%10.6%
ROE54.7%5.5%4.0%5.0%4.6%
ROIC36.4%4.2%3.8%4.5%4.1%
ROA36.0%3.7%2.5%3.3%3.0%
Debt / equity0.210.390.340.320.34
Interest coverage22.3x9.3x4.9x6.1x5.9x
Current ratio2.001.201.761.911.89
Revenue growth+20.2%+13.2%+8.6%+8.4%+5.1%
EPS growth+1,127.8%−96.7%−24.2%+32.4%−3.0%
P/E at year end1.8x35.1x52.9x53.7x36.9x
EV / EBITDA at year end8.0x18.4x20.3x22.0x16.2x
FCF yield at year end10.09%3.32%1.38%1.37%3.13%
Dividend payout0.1%0.8%1.0%0.0%0.0%

Revenue by segment

FY2021FY2022FY2023FY2024FY2025
Coopervision Segment$2.2B$2.2B$2.4B$2.6B$2.7B
Coopersurgical Segment$770.5M$1.1B$1.2B$1.3B$1.3B

Revenue by region · FY2025

UNITED STATES$2.7B · 46%
Europe$2.4B · 40%
Rest Of World, Excluding United States And Europe$785.2M · 13%

Street estimates by fiscal year

Next report 2026-12-03 · consensus EPS $1.07 · these are analysts' numbers, not ours
Fiscal yearRevenue (mean)Revenue rangeEPS (mean)EPS rangeAnalystsP/E on mean EPS
2026$4.2B$4.2B – $4.2B$4.54$4.53 – $4.551112.8x
2027$4.4B$4.4B – $4.4B$4.70$4.56 – $4.891112.3x
2028$4.6B$4.5B – $4.7B$5.11$4.40 – $5.75911.3x

Reported vs expected, every quarter on file

ReportedEPS expectedEPS actualEPS surpriseRevenue expectedRevenue actualRevenue surprise
2026-09-09$1.12$1.15+2.7%$1.1B$1.1B−2.9%
2026-06-04$1.10$1.21+10.0%$1.1B$1.1B+2.6%
2026-03-05$1.03$1.10+6.8%$1.0B$1.0B+0.0%
2025-12-04$1.11$1.15+3.6%$1.1B$1.1B+0.4%
2025-08-27$1.07$1.10+2.8%$1.1B$1.1B−0.3%
2025-05-29$0.93$0.96+3.4%$995.3M$1.0B+0.7%
2025-03-06$0.91$0.92+0.7%$978.1M$964.7M−1.4%
2024-12-05$1.00$1.04+4.0%$1.0B$1.0B−0.8%
2024-08-28$0.91$0.96+5.4%$997.3M$1.0B+0.6%
2024-05-30$0.83$0.85+2.5%$948.1M$942.6M−0.6%
2024-02-29$0.78$0.85+8.6%$915.9M$931.6M+1.7%
2023-12-07$0.87$0.870.0%$925.3M$927.1M+0.2%
2023-08-30$0.84$0.840.0%$923.1M$930.2M+0.8%
2023-06-01$0.75$0.77+2.7%$865.8M$877.4M+1.3%
2023-03-02$0.67$0.73+9.0%$834.9M$858.5M+2.8%
2022-12-08$0.77$0.69−10.4%$838.7M$848.1M+1.1%
2022-08-31$0.80$0.800.0%$830.0M$843.4M+1.6%
2022-06-02$0.85$0.81−4.7%$821.0M$829.8M+1.1%
2022-03-03$0.77$0.81+5.2%$739.8M$787.2M+6.4%
2021-12-02$0.84$0.82−2.4%$721.8M$759.1M+5.2%
2021-09-02$0.82$0.85+3.7%$738.0M$763.4M+3.4%
2021-06-03$0.78$0.85+9.0%$687.3M$719.5M+4.7%
2021-03-04$0.69$0.79+14.5%$585.0M$680.5M+16.3%
2020-12-03$0.78$0.79+1.3%$666.2M$681.6M+2.3%

Off-exchange (dark pool) volume, weekly

FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)
0.206-150.306-220.306-290.307-060.207-130.207-200.207-270.208-030.208-100.108-170.108-240.208-31
Week ofNotionalSharesTrades
2026-08-31$205.0M2,928,80064,780
2026-08-24$139.6M1,916,48549,858
2026-08-17$135.8M1,779,76842,918
2026-08-10$207.9M2,722,88155,881
2026-08-03$178.8M2,411,89657,832
2026-07-27$181.6M2,525,25959,784

Short-sale share of off-exchange volume

daily 20-day average
07-2310-1516.5%
DateShort shareShort volumeTotal volume
2026-10-1516.5%207,5581,254,850
2026-10-1412.4%170,1311,366,646
2026-10-1323.6%235,431996,876
2026-10-1232.6%591,1401,811,607
2026-10-0933.4%435,9991,305,820
2026-10-0841.5%756,2961,823,597
2026-10-0742.4%565,4961,333,000
2026-10-0629.2%485,7461,664,643
2026-10-0539.2%492,7501,255,945
2026-10-0237.7%449,5461,191,743
A daily flow measure from FINRA, not short interest.

Seasonality

Average return by calendar month
+3.0Jan+2.1Feb+2.9Mar+0.6Apr-0.0May+0.2Jun+1.2Jul+1.4Aug+1.4Sep-3.7Oct+1.1Nov+1.8Dec
MonthAvg returnUp yearsYears
Jan+3.0%75%20
Feb+2.1%65%20
Mar+2.9%67%21
Apr+0.6%60%20
May−0.0%45%20
Jun+0.2%55%20
Jul+1.2%55%20
Aug+1.4%55%20
Sep+1.4%55%20
Oct−3.7%40%20
Nov+1.1%60%20
Dec+1.8%55%20
History, not a forecast.

Indicators

as of 2026-10-16
RSI 1450.3
MFI56.9
ADX41.8
Stochastic %K / %D71.8 / 50.8
Williams %R-6.8
CCI159
TSI / signal-24.0 / -33.7
Chaikin money flow0.13
ATR$1.66
Bollinger width8.1%
Volume vs 20-day avg0.85x
SupertrendDown

Moving averages and bands

level (price vs level)
SMA 20$55.86 (+3.7%)
SMA 50$63.55 (−8.8%)
SMA 200$70.04 (−17.3%)
EMA 21$56.98 (+1.7%)
EMA 50$60.97 (−5.0%)
EMA 200$68.21 (−15.1%)
Bollinger upper$58.11 (−0.3%)
Bollinger lower$53.61 (+8.1%)
Parabolic SAR$53.79 (+7.7%)
Open the live chart, 110+ indicators

About The Cooper Companies, Inc.

The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.

https://www.coopercos.com

Key executives

NameTitlePayBorn
Albert G. WhitePresident, Chief Executive Officer & Non-Independent Director$2.7M1970
Daniel G. McBrideExecutive VP, COO General Counsel & Secretary$1.5M1964
Brian G. AndrewsExecutive VP, CFO & Principal Accounting Officer$1.3M1979
Holly R. SheffieldPresident of CooperSurgical, Inc.$1.1M1971
Gerard H. WarnerPresident of CooperVision, Inc.$1.1M1965
Kim DuncanVice President of Investor Relations & Risk Management——

Executive pay, latest proxy

ExecutiveYearSalaryStock awardsIncentiveTotal
Albert G. White III President & Chief Executive Officer2025$1.2M$6.6M$1.5M$16.1M
Daniel G. McBride Executive Vice President, Chief Operating Officer, General Counsel & Secretary2025$792,308$3.3M$639,236$4.8M
Brian G. Andrews Executive Vice President, Chief Financial Officer & Treasurer2025$734,615$1.5M$555,330$4.3M
Holly R. Sheffield President, CooperSurgical, Inc.2025$646,154$2.5M$435,539$3.7M
Gerard H. Warner III President, CooperVision, Inc.2025$634,615$2.5M$434,497$3.6M

Employees

12k201812k201912k202012k202114k202215k202316k202415k2025

Dividends

Ex-dateAmountPaid
2023-07-26$0.00752023-08-11
2023-01-20$0.00752023-02-10
2022-07-26$0.00752022-08-11
2022-01-20$0.00752022-02-09
2021-07-26$0.00752021-08-11
2021-01-21$0.00752021-02-09
2020-07-22$0.00752020-08-07
2020-01-22$0.00752020-02-10

Moat model

Weak · Efficient Scale · 2026-07-31
Cost advantage60
Intangibles44
Switching costs34
Network effect60
Efficient scale80
Our component scores (0-100) and overall 52.5; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms